ArticleEULAR rheumatology open2026
Spondyloarthritis and inflammatory bowel disease: towards a more severe and refractory disease phenotype.
Article in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The coexistence of inflammatory bowel disease (IBD) and spondyloarthritis (SpA) poses significant diagnostic and therapeutic challenges. This study aimed to compare clinical characteristics and treatment profiles of patients with both SpA and IBD (SpA/IBD) to those with SpA or IBD alone. Methods: We performed a single-centre observational study including 62 consecutive patients with SpA/IBD followed between 2019 and 2022. Patients met Assessment of SpondyloArthritis International Society 2009 criteria for SpA and had confirmed IBD. Demographics, clinical features, imaging, and biologic disease-modifying antirheumatic drug (bDMARD) usage were collected. For comparison, we included 100 patients with a single diagnosis of SpA or IBD, representing the Maladies Inflammatoires SysTémIques Chroniques cohort enrolled over the same period. Results: Among patients with SpA/IBD (51% male, 67% HLA-B27+), IBD was more often diagnosed first. Compared with SpA alone, patients with SpA/IBD had more psoriasis (27% vs 17%, Conclusions: Patients with SpA/IBD exhibit more severe disease and therapeutic challenges, highlighting the need for tailored management and consideration of earlier combination biologic therapies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.